Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain
Plus: BioNTech Signs Asia Deal
Executive Summary
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.